本文選題：沙美特羅替卡松 + 慢性阻塞性肺疾病�。� 參考：《中國臨床藥理學(xué)雜志》2017年11期

【摘要】：目的觀察沙美特羅替卡松治療慢性阻塞性肺疾病(COPD)臨床療效及安全性。方法將70例COPD患者隨機(jī)分為對照組35例與試驗組35例。2組均予以常規(guī)治療以及對癥治療;對照組予以噻托溴銨粉霧劑,每次一吸(18μg),qd;試驗組予以沙美特羅替卡松粉吸入劑,每次一吸(50μg),qd。2組患者一個周期均為28 d,共治療3個周期。比較2組患者的臨床療效、治療前后用力肺活量(FVC)、一秒用力呼氣容積(FEV1)、最大呼氣峰流速值(PEF)、FEV1/FVC、FEV1及PEF占預(yù)計值百分比、圣·喬治醫(yī)院呼吸問題調(diào)查問卷(SGRQ)、多因素分級系統(tǒng)(BODE)指數(shù)評分,以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗組和對照組的總有效率分別為91.43%(32/35例)和77.14%(27/35例),差異有統(tǒng)計學(xué)意義(P0.05)。治療后,試驗組和對照組的FEV1分別為(1.86±0.19),(1.42±0.17)L;FEV1/FVC分別為(42.93±4.25)%,(39.73±3.68)%;PEF分別為(3.69±0.37),(3.11±0.35)L;FEV1/預(yù)計值分別為(48.57±4.97)%,(44.47±4.51)%;PEF/預(yù)計值分別為(48.92±5.05)%,(41.53±4.55)%;SGBQ分別為(44.97±4.96),(42.01±4.67)分;BODE分別為(5.98±0.59),(5.67±0.59)分,差異均有統(tǒng)計學(xué)意義(均P0.05)。試驗組出現(xiàn)頭痛1例,震顫1例,心悸1例,總藥物不良反應(yīng)發(fā)生率為8.57%(3/35例),對照組出現(xiàn)頭痛2例,心悸1例,聲音嘶啞2例,總藥物不良反應(yīng)發(fā)生率為14.29%(5/35例),2組患者的藥物不良反應(yīng)發(fā)生率比較,差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論沙美特羅替卡松治療COPD的臨床療效顯著,安全性高。
[Abstract]:Objective to observe the efficacy and safety of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Methods 70 patients with COPD were randomly divided into control group (n = 35) and experimental group (n = 35). One cycle was 28 days in 50 渭 g / g QD.2 group, and there were 3 cycles of treatment. The clinical efficacy of the two groups was compared. Forced vital capacity (FVC), forced expiratory volume (FEV1), FEV1 / FEV1, FEV1 / FVC1 / FEV1 and PEF were compared between the two groups before and after treatment. The respiratory questionnaire of St. George's Hospital included SGRQN, multivariate grading system and BODEI score, and the incidence of adverse drug reactions (ADRs). Results after treatment, the total effective rates of the test group and the control group were 91.43 / 32 / 35 and 77.14 / 35, respectively. The difference was statistically significant (P 0.05). 娌葷枟鍚，

本文編號：1891511